Luvantas

Luvantas is a private biotechnology company focused on the development of next-generation incretin therapies for obesity and related cardiometabolic disorders. The company was founded by a team of experienced industry leaders, including former Gilead CEO John Milligan and former Eli Lilly executive David Kendall, to address the limitations of current weight-loss medications. Luvantas' lead candidate, LUV-101, is a long-acting tri-agonist that targets the GLP-1, GIP, and glucagon receptors to maximize metabolic benefits and weight reduction. By leveraging deep expertise in incretin biology, the company aims to provide more effective and better-tolerated treatment options for patients with metabolic diseases. Luvantas is headquartered in San Francisco and is supported by leading venture capital firms such as ARCH Venture Partners and GV.